Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-1β Allergy cVLP Vaccine
- Development stage
- Preclinical
- Lead developer
- AdaptVac
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The IL-1β Allergy cVLP Vaccine is a preclinical therapeutic vaccine candidate developed by AdaptVac for the treatment of allergic contact dermatitis. The vaccine utilizes AdaptVac's proprietary capsid virus-like particle (cVLP) platform, which employs the SpyTag/SpyCatcher protein ligation system to display antigens in a highly organized, repetitive array that mimics the structure of a virus. This architecture is designed to trigger a potent and durable immune response, inducing the production of endogenous antibodies that neutralize interleukin-1 beta (IL-1β). By targeting IL-1β, a central mediator of the inflammatory response in skin allergies, the vaccine aims to provide long-term relief from dermatitis symptoms with fewer administrations than traditional monoclonal antibody therapies.
- Other names
- IL-1beta Allergy cVLP VaccineIL1beta Allergy cVLP VaccineIL 1beta Allergy cVLP VaccineAdaptVac IL-1β vaccine
02
Targets
IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on IL-1β Allergy cVLP Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-1β Allergy cVLP Vaccine.